Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis

Wallwork, Ben, Coman, William, Mackay-Sim, Alan and Cervin, Anders (2004) Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis. The Laryngoscope, 114 2: 286-290. doi:10.1097/00005537-200402000-00019


Author Wallwork, Ben
Coman, William
Mackay-Sim, Alan
Cervin, Anders
Title Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis
Journal name The Laryngoscope   Check publisher's open access policy
ISSN 0023-852X
Publication date 2004-02
Sub-type Article (original research)
DOI 10.1097/00005537-200402000-00019
Open Access Status
Volume 114
Issue 2
Start page 286
End page 290
Total pages 5
Editor J. T. Johnson
Place of publication St. Louis, U.S.
Publisher Wiley-Blackwell
Collection year 2004
Language eng
Subject C1
321018 Otorhinolaryngology
730118 Organs, diseases and abnormal conditions not elsewhere classified
1103 Clinical Sciences
Abstract Objectives: Long-term, low-dose macrolide therapy is effective in the treatment of chronic rhinosinusitis. It is believed that macrolide antibiotics produce this benefit through an anti-inflammatory effect. In this study, the effect of clarithromycin treatment on the expression of transforming growth factor (TGF)-beta and the key pro-inflammatory nuclear transcription factor, NF-kappaB, was examined in vitro and in vivo. Study Design and Methods: In vitro: nasal mucosa was obtained from 10 patients with chronic sinusitis and was cultured for 24 hours in the presence of clarithromycin or control. Cellular expression of TGF-beta and NF-kappaB was determined by immunohistochemistry. In vivo: 10 patients with chronic rhinosinusitis were treated for 3 months with clarithromycin. Nasal mucosal biopsies were taken pre- and posttreatment. Cellular expression of TGF-beta and NF-kappaB was again determined by immunohistochemistry. Results: Clarithromycin, when applied to nasal biopsies in vitro, reduced cellular expression of TGF-beta and NF-kappaB. Nasal biopsies taken before and after clarithromycin treatment showed no differences in cellular expression of NF-kappaB or TGF-beta. Conclusion: Clarithromycin can reduce cellular expression of TGF-beta and NF-kappaB when applied in vitro, but its action during clinical therapy is less clear. Clarithromycin is capable of inhibiting pro-inflammatory cytokines in vitro, and reductions of TGF-beta and NF-kappaB may represent additional mechanisms by which macrolides reduce inflammation in chronic airway disease. Discrepancies between the actions of clarithromycin on nasal biopsies in vitro and after clinical therapy warrant further investigation.
Keyword Medicine, Research & Experimental
Otorhinolaryngology
Macrolide
Chronic Sinusitis
Nf-kappa B
Tgf-beta
Transcription Factor
Cytokine Production
Epithelial-cells
Erythromycin
Expression
Fibroblasts
Activation
Disease
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2005 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 26 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 36 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 04:53:51 EST